SMMT - Summit Therapeutics PLC logo

Summit Therapeutics PLC

SMMT

Summit Therapeutics develops and commercializes therapeutics focused on oncology, including ivonescimab, a bispecific antibody targeting PD-1 for non-small cell lung cancer and colorectal cancer. They operate in various global markets, including the U.S. and Europe.

⚕️ Healthcare NASDAQ Listed 2015 £ GBP
$1,000 invested 10 years ago →$1,282today

Score Overview

1 Year
Score—
Net Growth20.70%
Net TrendGrew
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
Score2.3
Net Growth-7x
Net Trend60%
Net Income Consistency—
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency—
10 Years
Score
Net Growth-38x
Net Trend50%
Net Income Consistency
Rev Growth-100.00%
Rev Trend30%
Revenue Consistency
All Time
Score
Net Growth-40x
Net Trend45%
Net Income Consistency
Rev Growth-100.00%
Rev Trend36%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Summit Therapeutics PLC has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. SMMT does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 15.47—
1 Year2025-10-23
$ 18.75-17.49%
5 Years2021-10-22
$ 4.98210.64%
10 Years2016-10-21
$ 12.0728.17%
All Time2015-03-05
$ 10.1951.82%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in GBP

Year
TTM£ 0.00-£ 856M£ 690M
2025£ 0.00-£ 1.07B£ 529M
2024£ 0.00-£ 176M£ 329M
2023£ 0.00-£ 482M£ 147M
2022£ 583.19K-£ 65M£ 284M
2021£ 1M-£ 86M£ 53M
2020£ 628.88K-£ 38M£ 48M
2019£ 43M£ 4M£ 49M
2018£ 57M£ 10M£ 35M
2017£ 14M-£ 20M£ 28M
2016£ 2M-£ 21M£ 35M
IPO2015£ 1M-£ 20M£ 23M
SMMT - Summit Therapeutics PLC logo

Summit Therapeutics PLC fundamental performance

Between 2020 and 2025, revenue declined from £ 628.88K to £ 0.00 and net income went from -£ 38M to -£ 1.07B. Revenue increased in 0 of those 5 years; net income in 3.

Across Summit Therapeutics PLC's full reported history, from 2015 to 2025, revenue declined from £ 1M to £ 0.00 and net income went from -£ 20M to -£ 1.07B. Revenue increased in 36% of the years measured; net income in 45%.

Summit Therapeutics PLC currently holds a 5-year HDB Score of 2.3 out of 10. How the HDB Score is calculated.

Membership

Explore SMMT with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies